Scientists in Japan have developed a groundbreaking treatment that could double the average lifespan of cats, extending it from around 15 years to nearly 30 years. The key lies in a protein called AIM (Apoptosis Inhibitor of Macrophage), discovered by Dr. Toru Miyazaki. While cats naturally produce AIM, they lack the ability to activate it effectively. This deficiency leads to the gradual buildup of waste in the kidneys, the leading cause of death in domestic cats. Dr. Miyazaki’s team created an injectable form of activated AIM that directly restores the kidneys’ natural cleaning function. In clinical trials, cats with advanced kidney disease showed dramatic improvement after treatment. The therapy works both as a preventive measure for healthy cats and as a treatment for those already ill. If approved, the treatment could revolutionize feline healthcare. Commercial rollout is expected to begin in Japan as early as 2025, with wider availability projected for 2027. The research has also sparked interest for its potential applications in human medicine, as the AIM protein plays a similar waste-clearing role across species.